|Bid||2.8500 x 1100|
|Ask||2.9000 x 1400|
|Day's Range||2.6000 - 2.8800|
|52 Week Range||2.4600 - 9.0700|
|Beta (5Y Monthly)||1.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
Subscribe to Yahoo Finance Plus to view Fair Value for VYGRLearn more
Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow...
Novel intravenous (IV) vectorized antibody approach designed to activate innate immune system, destroy metastatic breast cancer tumors, and inhibit tumor progression in CNS Proprietary TRACER™ capsid screening technology enables broad expression of vectorized antibody in mouse brain TRACER AAV vector encoding anti-HER2 antibody demonstrated tumor reduction across multiple mouse models and survival benefit CAMBRIDGE, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYG
The list, released Wednesday, ranks the fastest-growing technology, media, telecommunications and life sciences companies based in North America.